Sigilon Therapeutics
Michael Owings has a strong background in quality and regulatory compliance. Michael most recently served as the Head of Quality at Sigilon Therapeutics, Inc. Prior to that, they held the position of Vice President of Regulatory and Quality Compliance at TraceLink. Michael also has experience as the Vice President of Quality and Regulatory Compliance at PHT Corporation and Oracle, where they managed a team and implemented quality management systems. Earlier in their career, they worked at Phase Forward in various roles, including Vice President of Quality and Regulatory Compliance and Director of Quality and Regulatory Compliance.
Michael Owings earned a B.S in Chemistry from the University of Missouri-Kansas City. No specific start or end year was provided.
Sigilon Therapeutics
2 followers
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.